Project
Amiselimod
Automatically Closed · 2017 until 2022
Knellwolf Christina, Dora Barbara, Krieger-Grübel Claudia, Sulz Michael
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
2017
End Date
2022
Financing
Industry
Brief description/objective
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study of Amiselimod (MT-1303) in the Induction and Maintenance of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis